Charles River Laboratories International (NYSE:CRL) EVP Sells $1,327,098.00 in Stock

Charles River Laboratories International, Inc. (NYSE:CRL) EVP Shannon Parisotto sold 5,046 shares of the firm’s stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $263.00, for a total transaction of $1,327,098.00. Following the transaction, the executive vice president owned 4,807 shares of the company’s stock, valued at approximately $1,264,241. This represents a 51.21% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Charles River Laboratories International Price Performance

NYSE:CRL traded up $5.01 during trading hours on Thursday, reaching $265.73. The company had a trading volume of 1,306,837 shares, compared to its average volume of 926,372. Charles River Laboratories International, Inc. has a one year low of $144.26 and a one year high of $268.00. The company has a quick ratio of 1.03, a current ratio of 1.36 and a debt-to-equity ratio of 0.90. The stock has a 50-day moving average of $211.45 and a two-hundred day moving average of $188.38. The firm has a market capitalization of $12.80 billion, a PE ratio of -70.67, a PEG ratio of 2.61 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.77 by $0.25. The business had revenue of $1 billion during the quarter, compared to analysts’ expectations of $977.20 million. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The firm’s revenue for the quarter was down 2.7% on a year-over-year basis. During the same quarter last year, the company posted $3.12 EPS. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Analysts forecast that Charles River Laboratories International, Inc. will post 11.05 earnings per share for the current year.

Institutional Trading of Charles River Laboratories International

A number of hedge funds and other institutional investors have recently made changes to their positions in CRL. Invesco Ltd. increased its position in shares of Charles River Laboratories International by 115.8% in the fourth quarter. Invesco Ltd. now owns 2,696,150 shares of the medical research company’s stock valued at $537,828,000 after acquiring an additional 1,446,972 shares during the last quarter. Massachusetts Financial Services Co. MA acquired a new stake in Charles River Laboratories International during the 4th quarter valued at $176,478,000. Victory Capital Management Inc. boosted its holdings in shares of Charles River Laboratories International by 9,938.8% during the 4th quarter. Victory Capital Management Inc. now owns 691,474 shares of the medical research company’s stock worth $137,935,000 after buying an additional 684,586 shares during the period. Ameriprise Financial Inc. raised its holdings in Charles River Laboratories International by 1,491.1% in the 3rd quarter. Ameriprise Financial Inc. now owns 613,604 shares of the medical research company’s stock valued at $96,005,000 after acquiring an additional 575,039 shares during the period. Finally, Amundi lifted its position in Charles River Laboratories International by 175.2% during the first quarter. Amundi now owns 773,315 shares of the medical research company’s stock worth $133,397,000 after acquiring an additional 492,301 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Mizuho increased their price target on shares of Charles River Laboratories International from $192.00 to $230.00 and gave the company a “neutral” rating in a research note on Monday, July 13th. Royal Bank Of Canada increased their price objective on Charles River Laboratories International from $215.00 to $282.00 and gave the company an “outperform” rating in a research report on Thursday. Sanford C. Bernstein set a $250.00 target price on Charles River Laboratories International in a research note on Wednesday, July 1st. BNP Paribas Exane set a $250.00 price target on Charles River Laboratories International in a research note on Wednesday, July 1st. Finally, CLSA cut Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 price target on the stock. in a report on Monday, July 20th. Twelve analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $244.19.

More Charles River Laboratories International News

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: JPMorgan upgraded CRL to “overweight” and raised its price target to $310 from $180, implying additional upside and signaling increased confidence in the company’s earnings recovery and demand outlook. Benzinga
• Positive Sentiment: Second-quarter results exceeded Wall Street expectations: adjusted earnings were $3.02 per share versus the $2.77 consensus, while revenue of approximately $1.0 billion topped estimates of $977.2 million. The earnings beat helped support the stock’s advance. Charles River Laboratories Q2 Earnings and Revenues Surpass Estimates
• Positive Sentiment: CRL raised its 2026 outlook to EPS of $11.15–$11.45 and revenue of roughly $3.9 billion, both ahead of analyst expectations. It also increased projected free cash flow to $400 million–$420 million. Charles River 2026 Outlook
• Positive Sentiment: Management cited improving biotech demand, stronger drug-discovery order trends and anticipated margin benefits from cost reductions and divestitures. The Discovery and Safety Assessment business reportedly has a healthy backlog and book-to-bill ratio. Charles River Lifts Profit Forecast

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.